Rohto Pharmaceutical (4527) Q2 2025 earnings summary

Executive summary

• Net sales rose 8.8% year-over-year to ¥139,082 million for the six months ended September 30, 2024, driven by strong domestic and overseas demand and favorable currency effects.

• Operating income declined 15.1% year-over-year to ¥17,791 million due to higher cost of sales and increased SG&A, including R&D expenses.

• Profit attributable to owners of parent fell 22.1% year-over-year to ¥12,921 million.

Financial highlights

• Gross profit increased to ¥78,507 million from ¥73,960 million year-over-year.

• Ordinary income decreased 18.0% year-over-year to ¥18,590 million.

• Net income per share was ¥56.64, down from ¥72.74 in the prior year period.

• Comprehensive income dropped 27.9% year-over-year to ¥19,133 million.

Outlook and guidance

• Full-year forecast maintained: net sales ¥320,000 million (+18.2% YoY), operating income ¥43,200 million (+7.9% YoY), profit attributable to owners of parent ¥32,200 million (+4.1% YoY), EPS ¥141.14.

• Interim dividend set at ¥17.00 per share; full-year forecast at ¥33.00 per share.